EPIX vs. NBTX, FBLG, AQST, PROC, AKBA, VSTM, URGN, XOMA, INZY, and VNDA
Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Nanobiotix (NBTX), FibroBiologics (FBLG), Aquestive Therapeutics (AQST), Procaps Group (PROC), Akebia Therapeutics (AKBA), Verastem (VSTM), UroGen Pharma (URGN), XOMA (XOMA), Inozyme Pharma (INZY), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Nanobiotix (NASDAQ:NBTX) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.
38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 14.7% of ESSA Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ESSA Pharma's return on equity of 0.00% beat Nanobiotix's return on equity.
In the previous week, ESSA Pharma had 2 more articles in the media than Nanobiotix. MarketBeat recorded 2 mentions for ESSA Pharma and 0 mentions for Nanobiotix. ESSA Pharma's average media sentiment score of 0.00 beat Nanobiotix's score of -1.00 indicating that Nanobiotix is being referred to more favorably in the media.
ESSA Pharma has lower revenue, but higher earnings than Nanobiotix.
ESSA Pharma received 338 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 76.32% of users gave ESSA Pharma an outperform vote while only 62.50% of users gave Nanobiotix an outperform vote.
Nanobiotix currently has a consensus price target of $11.00, indicating a potential upside of 64.92%. ESSA Pharma has a consensus price target of $16.50, indicating a potential upside of 164.00%. Given Nanobiotix's higher possible upside, analysts clearly believe ESSA Pharma is more favorable than Nanobiotix.
Nanobiotix has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.
Summary
ESSA Pharma beats Nanobiotix on 8 of the 13 factors compared between the two stocks.
Get ESSA Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ESSA Pharma Competitors List
Related Companies and Tools
